1. The effects of alendronate on the suppression of bone resorption and the promotion of cartilage formation in the human mosaicplasty donor site: A randomized, double-blind, placebo-controlled prospective study.
- Author
-
Nakagawa, Yasuaki, Mukai, Shogo, Mori, Koji, Yabumoto, Hiromitsu, Nakamura, Ryota, and Shinya, Yuki
- Subjects
- *
BONE resorption , *PATELLOFEMORAL joint , *BONE grafting , *CARTILAGE , *ALENDRONATE , *MAGNETIC resonance imaging , *BONE growth , *KNEE joint , *RESEARCH , *CHONDROGENESIS , *ANIMAL experimentation , *RESEARCH methodology , *RABBITS , *EVALUATION research , *AUTOGRAFTS , *COMPARATIVE studies , *RANDOMIZED controlled trials , *ARTICULAR cartilage , *LONGITUDINAL method , *PHARMACODYNAMICS - Abstract
Background: We previously reported that early alendronate administration accelerated bone formation and improved the quality of repaired cartilage in the donor site in rabbits. To investigate whether alendronate administration has effects in humans similar to those observed in rabbits.Methods: The study cohort included 35 patients over the age of 12-years old who underwent mosaicplasty without osteoporotic therapy from March 2011 to October 2012. The donor sites were medial or lateral in the patellofemoral joint. Placebo (P) or Bonalon containing 35 mg of alendronate (A) was administered orally every week for 8 weeks. The cohort comprised 15 male and 20 female, including 14 right and 21 left knees. The mean age at the time of surgery was 57.1 years. Bone formation was examined using computer tomography and lateral knee radiography, and cartilage formation was examined using magnetic resonance imaging (MRI), second-look assessment, and intraoperative acoustic evaluation. The clinical outcomes were assessed using the Japanese Orthopaedic Association knee score and visual analog scale (VAS). Bone and cartilage formation in the donor site and clinical outcomes were assessed at 3, 6, and 12 months after mosaicplasty.Results: The ratio of TRAP-5b in group A was significantly smaller than that in group P at 2 and 8 weeks after mosaicplasty. The extent of bone formation in the donor sites in group A was significantly greater than that in group P at 3 and 6 months after mosaicplasty. Cartilage formation did not differ significantly between the two groups as determined by MRI, macroscopic assessment, and intraoperative acoustic evaluation. Clinical outcomes did not differ significantly between the two groups, and no negative clinical outcomes were observed.Conclusion: Early alendronate administration accelerated bone formation but not cartilage formation in the mosaicplasty donor site in humans. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF